EMA/898472/2022

European Medicines Agency decision

P/0507/2022

of 2 December 2022

on the refusal of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol), (EMEA-000637-PIP02-10-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.

European Medicines Agency decision

P/0507/2022

of 2 December 2022

on the refusal of a modification of an agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol), (EMEA-000637-PIP02-10-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/284/2010 issued on 3 December 2010, the decision P/279/2011 issued on 28 November 2011, and the decision P/0057/2012 issued on 26 March 2012, the decision P/0037/2014 issued on 5 March 2014, the decision P/0232/2016 issued on 9 September 2016 and the decision P/0303/2018 issued on 12 September 2018,

Having regard to the application submitted by Takeda Pharmaceuticals International AG Ireland Branch submitted on 8 June 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the refusal of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lanthanum carbonate hydrate (Fosrenol), chewable tablets, oral powder, oral use, including changes to the deferral, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby refused.

Article 2

This decision is addressed to Takeda Pharmaceuticals International AG Ireland Branch, Block 3 Miesian Plaza, 50 - 58 Baggot Street Lower, D02 Y754 - Dublin 2, Ireland.

EMA/640012/2022
Amsterdam, 14 October 2022

Opinion of the Paediatric Committee on the refusal of a modification of an agreed Paediatric Investigation Plan

EMEA-000637-PIP02-10-M07

Scope of the application

Active substance(s):

Lanthanum carbonate hydrate

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of hyperphosphataemia

Pharmaceutical form(s):

Chewable tablets

Oral powder

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Takeda Pharmaceuticals International AG Ireland Branch

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharmaceuticals International AG Ireland Branch submitted to the European Medicines Agency on 8 June 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/284/2010 issued on 3 December 2010, the decision P/279/2011 issued on 28 November 2011, and the decision P/0057/2012 issued on 26 March 2012, the decision P/0037/2014 issued on 5 March 2014, the decision P/0232/2016 issued on 9 September 2016 and the decision P/0303/2018 issued on 12 September 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 August 2022.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends, as set out in the appended summary report:

    - to refuse the changes proposed by the applicant regarding the paediatric investigation plan and the deferral.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver remain unchanged and are set out in the Annex I.

3. The scientific conclusions and the grounds for refusal are set out in the summary report appended to this opinion.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hyperphosphataemia

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- chewable tablets, oral powder, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe;

and to:

- infants and children from 6 months to less than 10 years of age;
- chewable tablets, oral powder, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of hyperphosphataemia

2.1.1. Indication(s) targeted by the PIP

Treatment of hyperphosphataemia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Chewable tablets, oral powder

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of a 250mg oral powder formulation
Non-clinical studies	**Study 2** 6-week repeat-dose toxicity study in juvenile rats
Clinical studies	**Study 3** Open-label study to investigate efficacy, safety and tolerability of lanthanum carbonate, and to assess pharmacokinetic profiles of

	lanthanum carbonate in hyperphosphataemic children and adolescents from 10 to less than 18 years of age with chronic kidney disease (CKD) on dialysis
Extrapolation, modelling and simulation studies	**Study 4** Extrapolation from the dose-response in adult to paediatric chronic kidney disease (CKD) patients on dialysis
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2019
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s):

1. Treatment of hyperphosphataemia

Authorised indication(s):

- Fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Authorised pharmaceutical form(s):

Chewable tablet, oral powder

Authorised route(s) of administration:

Oral use